Furthermore, we place specific emphasis on MOv18 IgE, as the first-in-class agent that has undergone extensive pre-clinical efficacy and safety evaluations in several model systems, prior to reaching clinical testing in patients with cancer. This evidence concerns the gene IGHE and cancer.